1 / 41

Failure To Thrive FTT

Failure To Thrive FTT. Michal Kori M.D. Pediatric Gastroenterology. Failure to thrive (FTT) is a sign that describes a particular problem rather than a diagnosis. The term FTT is used to describe instances of growth failure or, more specifically, failure to gain weight appropriately.

Télécharger la présentation

Failure To Thrive FTT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Failure To ThriveFTT Michal Kori M.D. Pediatric Gastroenterology

  2. Failure to thrive (FTT) is a sign that describes a particular problem rather than a diagnosis. • The term FTT is used to describe instances of growth failure or, more specifically, failure to gain weight appropriately. • In more severe cases, linear growth and head circumference also may be affected.

  3. Definition • There is no consensus regarding the definition of failure to thrive. • FTT may be attributed to a child with any of the following: • Weight <2nd percentile for age and sex on more than one occasion • Weight <80 percent of ideal body weight for age and sex • Weight that is depressed in proportion to height • A weight trajectory that crosses two or more major percentile lines over time • A rate of daily weight gain less than expected for age

  4. Daily weight gain expected for age • 26 to 31 g/day for those 0 to 3 months • 17 to 18 g/day for those 3 to 6 months • 12 to 13 g/day for those 6 to 9 months • 9 to 13 g/day for those 9 to 12 months • 7 to 9 g/day for those 1 to 3 years

  5. Expected changes in weight and length

  6. Infants and young children with genetic short stature, constitutional growth delay, prematurity, or intrauterine growth restriction (IUGR) who have appropriate weight for length and normal growth velocity are not considered to have FTT.

  7. Measurement and growth • Accurate assessment of the child's weight, length, and head circumference is essential. • In the child < 2 years, the recumbent length, should be obtained. • Height (length), weight, weight for length, and head circumference, should be plotted on a standardized growth chart. • Two growth charts are available; • World Health Organization (WHO) growth charts • (CDC/NCHS) Centers for Disease Control and Prevention and National Center for Health Statistics growth charts

  8. Growth trajectory • The growth trajectory is assessed by plotting the child's growth parameters at various ages on a growth chart standardized for sex, age, and medical condition (eg, Down syndrome). • Special attention should be paid to the timing of changes in the slopes of the weight, length, or head circumference trajectories. • What happened at that point in the child's life: initiation of complementary foods? Onset of diarrhea? Parental stressor

  9. Normal growth parameters at birth deceleration in weight, followed by deceleration in stature z"stunting", and finally deceleration in head circumference is characteristic of inadequate nutritional intake. As stunting develops, the weight for length may return toward normal. • Normal growth parameters at birth with simultaneous deceleration in length and weight before two years of age and normal growth velocity after two years of age is suggestive of genetic short stature or constitutional growth delay. These normal growth patterns are often confused with FTT. • Deceleration of head circumference before deceleration in weight or length is suggestive of a neurologic disorder

  10. Proportionality • Decreased weight in proportion to length ("wasting") reflects inadequate nutritional intake. • Decreased length in proportion to weight is suggestive of an endocrinologic abnormality. • Decreased length with a proportionate weight may be nutritional (if long-standing), genetic, or endocrine in origin. • When head circumference is impaired as much as, or more than, weight or length, intrauterine infection, teratogenic exposures, congenital syndromes, and other causes of microcephaly should be considered.

  11. Risk factors for FTT • Medical risk factors • Prematurity, (particularly when associated with IUGR) • Developmental delay, • Congenital anomalies (eg, cleft lip and/or palate), • Intrauterine exposures (eg, alcohol, anticonvulsants, infection) • Any medical condition that results in inadequate intake, increased metabolic rate, maldigestion or malabsorption • Psychosocial risk factors • Poverty, • Certain health and nutrition beliefs, disordered feeding techniques • Social isolation • Life stresses • Poor parenting skills • Substance abuse • Psychopathology, violence, and abuse

  12. Etiology- three major catagories • Inadequate dietary energy intake, • Inadequate nutrient absorption, • Increased energy requirements • The majority of cases in primary care practice are secondary to inadequate dietary energy intake, usually related to psychosocial factors or disturbance in feeding behavior.

  13. Traditional classification of FTT

  14. Nutritional deprivation in infancy may be related to severe, irreversible developmental deficits and behavior problems. • The goal of the evaluation of a child with FTT is to identify the potential contributing factors so that each one may be addressed systematically. • The involvement of a dietitian, occupational or speech therapist, social worker, and/or developmental and behavioral pediatrician can be helpful in gathering this information and formulating a management plan.

  15. Evaluation • Medical history • Physical examination • Social status and problems • Nutritional evaluation • Developmental evaluation

  16. Medical History (1) • Perinatal- pregnancy, drugs, alcohol etc. • Birth weight- LGA, SGA (IUGR, symetrical, asymetrical), prematurity • Postnatal problems- asphyxia, NEC, BPD • Prior medical problems- infections, hospitalizations, • Family history of disease, FTT, weight and height of parents and siblings.

  17. Medical History (2) • Detailed information regarding nutritional intake and feeding should be obtained, including information related to the duration of mealtimes, the type of food, and the quantity of food consumed • breast feeding / formula, amounts, preparation, introduction of new foods (when?), mother child interaction during feeding, fatigue, crying etc. • Stools- number per day, consistency • Vomiting

  18. The psychosocial history should include an assessment of psychosocial stressors and family strengths and resources. • Children with FTT should undergo formal developmental and behavioral testing.

  19. Diarrhea Chronic constipation Recent travel to developing country, camping, housing in shelter, day care Chronic otitis media Snoring or mouth breathing History of wheezing Vomiting or spitting up Gagging, tactile hypersensitivity, prolonged feeding time Polyuria, polydipsia, polyphagia Frequent infections Malabsorption -celiac disease, cystic fibrosis, lactase deficiency) May cause decreased appetite Infectious diarrhea (eg, giardiasis, nematodes, enteric pathogens) Immune deficiency; structural abnormality that impairs intake Adenoidal hypertrophy Mechanical obstruction, chronic pulmonary disease Gastroesophageal reflux, delayed gastric emptying, intestinal obstruction Oral motor dysfunction Diabetes Immune deficiency Historical clues to potential organic causes of failure to thrive

  20. Physical Examination • Observation- general appearance, signs of neglect, hygiene • Malnutrition- decreased subcutaneous fat bony prominence, protuberant abdomen, flat buttocks, muscle wasting, poor tone. • Full physical exam • Anthropometric measurements

  21. Laboratory evaluation • Laboratory evaluation for organic disease should be guided by the signs and symptoms found in the initial evaluation. • Basic routine testing; • CBC • Urine analysis • SMA (albumin) • Liver function

  22. Cholesterol +TG Blood Gases Immunoglobulins HIV TSH, T4 Fe, ferritin Folic acid, B12 Zn Stool culture and parasites xylose Celiac screen Sweat test GH studies More detailed testing

  23. Therapy • Therapy is directed at the major medical problem: malnutrition and its complication. • Nutritional assessment, current daily intake, prescribe 1.5-2 RDA calories and protein to allow “ catch-up” growth, add iron and vitamins when needed. • Close follow-up. • Attention to social problems.

  24. Maldigestion and Malabsorption

  25. Maldigestion and Malabsorption • Characterized clinically by by chronic diarrhea, distended abdomen and FTT

  26. The stages of digestion and absorption • Luminal hydrolysis and solubilization of carbohydrates, fat and proteins by enzymes secreted from salivary glands, the gastric mucosa and the pancreas • Hydrolysis at the enterocyte membrane (of peptides and disaccarides by border enzymes) • Absorption across the enterocyte membrane and cellular processing • Uptake from the enterocyte into the blood and lymph

  27. CarbohydratesIntraluminal digestion • Carbohydrates that undergo intraluminal digestion : • Starch (50-60%) -amylose, amylopectin (both are high MW polymers of glucose) they are broken down by amylase (saliva, gastric, pancreatic) to maltose, maltriose, and branched alpha limit dextrins. • Sucrose (30-40%) • Lactose (40-50%- infants, 0-20% adults)

  28. Brush border disacharridases • Glucoamylase- Breaks down 20-25% of maltose to free glucose. Releases free glucose from gl-polymers. • Sucrose-isomaltose1. Splits 100% of sucrose to gl + fructose 2. Splits 75-80% of maltose in to free gl. • Lactase -phlorizine - splits lactose into glucose + galactose.

  29. Absorption across the enterocytecarrier molecules • Glucose-galactose -Na dependent by an electromechanical gradient which is maintained by an Na-K ATPase on the basolateral membrane. • Fructose Carrier - non Na dependent

  30. Carbohydrate Malabsorption • Fermentative diarrhea • Distended abdomen • Acidic stools- pH 4.0-5.5 • Unabsorbed reducing substances in the stool

  31. ProteinsIntraluminal digestion • Starts in the stomach with denaturation of protein by gastric acid. • Pepsinogen I and II become activated. • In the duodenum: enterokinase activates trypsinogen into trypsin which activates zymogens in to active proteases.

  32. ProteinsIntraluminal digestion (cont.) • Endopeptidases • trypsin- amino basic acids • chemotrypsin- aromatic a.a. • elastase- charged small a.a. • Exopeptidases - frees terminal a.a. • Carboxypeptidase A- aromatic, neutral, acid • Carboxypeptidase B- basic

  33. Hydrolysis at enteroctye membraneand absorption • There are at least 8 brush border peptidases • Most amino acids are absorbed as dipeptides and tripeptides. • There are at least 4 amino acid transport systems which are all active- Na dependent. • No specific defect of peptide digestion and absorption by intestinal mucosa is known. • There are specific defects that are diagnosed due to aminoaciduria.

  34. FatIntraluminal digestion • Starts in the stomach with fundic lipase (pH- 3.5-5.5) • In the duodenum: 1. Pancreatic enzymes- lipase, co-lipase 2. Bile acids (cholic, chenodeoxycholic acid, are synthesized in the liver) (absorbed in the terminal ileum by Na dependent carrier mediated process)

  35. FatMicelle formation and absorption • Mixed micelles contain FFA, monoglycerides diglycerides, cholesterol esters, fat soluble vitamins. • Micelles diffuse into the enterocyte. In the cell FFA bind to carrier proteins FABP in the endoplasmic reticulem. • Long chain FA are activated by acyle CoA to monoglycerides

  36. FatCellular processing • MTP- Microsomal TG Transfer Protein, passes resynthesized TG from the ER to the golgi adding PL, Cholesterol and apo-proteins (B48). • In the golgi cylomicrones are formed and are secreted from the cell by exocytosis to the lymphatic system.

More Related